Long term follow-up of patients with prolactinomas and outcome of dopamine agonist withdrawal: a single center experience
- 17 March 2011
- journal article
- research article
- Published by Springer Nature in Pituitary
- Vol. 15 (1) , 25-29
Abstract
Dopamine agonists (DA) are the mainstay of treatment for patients with prolactinomas. To describe the efficacy of treatment and the outcomes of DA withdrawal. Retrospective review of electronic medical records of patients with prolactinomas from 1985 to 2009. Seventy-nine patients (17 men/62 women), aged 35.3 ± 1.6 years at diagnosis were studied. The mean follow-up time was 84.7 ± 9.2 months (range 0–336). The mean initial size of microadenomas was 0.74 ± 0.10 cm (range 2.41 ± 0.39) and of macrodenomas 2.41 ± 0.39 cm (range 1.1–8) and serum prolactin (PRL) levels were 112 ± 19 and 263 ± 59 ng/ml, respectively (normal range 0–40). Fifty-one (65%) prolactinomas were micro- and 28 (35%) were macroadenomas. DA led to a decrease in adenoma size in 71% of them, while 53% of microadenomas were not visible during follow-up. In 26 patients, DA withdrawal was decided. After therapy of >24 months and a mean follow-up time of 49 ± 11 months (range 3–168), 15 subjects (58%) showed no recurrence of hyperprolactinemia. Higher remission rates, although not statistically significant, were observed with cabergoline (75%). The mean PRL levels before DA discontinuation were 12.2 ± 2.3 ng/ml (range 0.5–44.7) and after discontinuation they were significantly lower than pre-treatment values. Recurrence of hypeprolactinemia was evident during the first year in all but one patient. Remission rates were not associated with age or size of adenoma at diagnosis, initial or before DA discontinuation PRL levels and duration of treatment. DA withdrawal was followed by remission of hyperprolactinamia in about half of patients after >2 years of treatment.Keywords
This publication has 24 references indexed in Scilit:
- Factors determining the remission of microprolactinomas after dopamine agonist withdrawalClinical Endocrinology, 2010
- Recurrence of Hyperprolactinemia after Withdrawal of Long-Term Cabergoline TherapyThe Journal of Clinical Endocrinology & Metabolism, 2009
- Predictors of remission of hyperprolactinaemia after long‐term withdrawal of cabergoline therapyClinical Endocrinology, 2007
- Guidelines of the Pituitary Society for the diagnosis and management of prolactinomasClinical Endocrinology, 2006
- Long‐term remission following withdrawal of dopamine agonist therapy in subjects with microprolactinomasClinical Endocrinology, 2005
- Withdrawal of Long-Term Cabergoline Therapy for Tumoral and Nontumoral HyperprolactinemiaNew England Journal of Medicine, 2003
- Long-Term Follow-Up of Prolactinomas: Normoprolactinemia after Bromocriptine WithdrawalThe Journal of Clinical Endocrinology & Metabolism, 2002
- Long-Term and Low-Dose Treatment with Cabergoline Induces Macroprolactinoma ShrinkageThe Journal of Clinical Endocrinology & Metabolism, 1997
- Withdrawal of bromocriptine after long‐term therapy for macroprolactinomas; effect on plasma prolactin and tumour sizeClinical Endocrinology, 1991
- EFFECT OF DOPAMINE AGONIST WITHDRAWAL AFTER LONG-TERM THERAPY IN PROLACTINOMASThe Lancet, 1984